Kornimate/medical-research-clean huggingface dataset:
effects of glucagon-like-peptide-1 analogues on sexuality

Conditions: Sexual Desire

Summary: this study is to investigate the effects of glp-1 analogues (combined with lifestyle interventions in comparison to lifestyle interventions only) on sexual desire, mood, quality of life, the reproductive axis, retinal vessel diameters, physical fitness (and semen, for men only) in overweight or obese men and women.

glucagon-like peptide-1 (glp-1) analogues are widely used for the treatment of type 2 diabetes mellitus due to its well-known insulinotropic effects as well as for the treatment of obesity due to its satiation-promoting and appetite- suppressant effects. the glp-1 analogues are approved in patients with obesity (bmi ≥ 30 kg/m2) or who are overweight (bmi ≥ 27 kg/m2) with additional comorbidities, such as prediabetes, diabetes mellitus type 2, arterial hypertension or dyslipidemia. beside its influence on the reward for palatable food, several studies have shown that glp-1 analogues modulate the rewarding effects of addictive drugs such as alcohol, nicotine and cocaine. as a further natural reward, sexual desire could be affected by glp-1 analogues likewise. this study investigates the influence of glp-1 analogues on sexuality in a population of overweight and obese participants. a treatment with a glp-1 analogue combined with lifestyle modifications for weight reduction will be compared to weight reduction with conventional lifestyle modifications only. in the context of the increasing use of glp-1 analogues, particularly in young people with reproductive desire, laboratory analyzes of the reproductive axis (hormones and sperm cells) will be part of this study to document a possible influence. mood changes, physical activity and fitness and effects on microvascular endothelial functioning by measuring diameters of retinal vessels will be further investigated.

Eligibility criteria:
inclusion criteria: * bmi ≥ 27 kg/m2 * willingness to lose weight by lifestyle changes only or by lifestyle changes plus glp-1 analogue treatment as agreed in a routine clinical appointment * active sex life (sex with partner or masturbation ≥2x/month) * eugonadism: * men: morning total testosterone ≥12mmol/l or free testosterone ≥ 0.198 nmol/l if\ 50 years old * women: no primary or secondary amenorrhea (inclusive menopause) \*secondary amenorrhea is defined as "absence of menses for more than three months in women who previously had regular menstrual cycles or six months in women who had irregular menses". exclusion criteria: * diabetes mellitus, hba1c ≥ 6,5 % * previous use of glp-1 analogues during last 2 months. * exogenous testosterone substitution * current illicit drug abuse * pregnancy

Keywords: glucagon-like-peptide-1 (glp-1) glucagon-like peptide-1 (glp-1) analogues obesity sexuality liraglutide (saxenda®) obese men reproductive axis microvascular endothelial function retinal vessels physical activity physical fitness mood sperm cells
sarizotan hc1 in patients with parkinson's disease suffering from treatment-associated dyskinesia

Conditions: Parkinson's Disease; Dyskinesia

Summary: the purpose of this study is to determine if sarizotan hc1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of parkinson's disease (pd).


Eligibility criteria:
inclusion criteria: * the subject is an out-patient. * the subject presents with a diagnosis of idiopathic parkinson's disease. * prior therapy with all registered parkinsonian medication is allowed. exclusion criteria: * (for female subjects) the subject is pregnant or lactating. * the subject is participating in another clinical study or has done so within the past 30 days. * the subject has received neurosurgical intervention related to pd. * the subject has relevant renal impairment. * the subject has relevant hepatic impairment. * the subject is suffering from any dementia or psychiatric illness. * the subject has a history of allergic asthma.

Keywords: parkinson's disease dyskinesia dyskinesia associated with dopaminergic treatment
hiv risk reduction and drug abuse treatment in iran

Conditions: Opiate Dependence; HIV Infections

Summary: a randomized, double blind clinical trial comparing buprenorphine and naltrexone maintenance treatment when combined with drug abuse and hiv risk reduction counseling (dc-hiv) for heroin and opium addicts in iran.

this randomized double blind clinical trial compares the efficacy of buprenorphine maintenance treatment (bmt) and naltrexone maintenance treatment (nmt) for recently detoxified opioid dependent patients (n=130; 65 heroin dependent, 65 opium dependent-specific aim 1). manual-guided, hiv risk reduction and drug counseling (dc-hiv) is provided to all patients as the platform psychotherapy. maintenance treatment is provided for 12 weeks to all patients; patients may also continue to receive maintenance treatment for an additional 12 weeks following the initial treatment period. primary outcome measures, assessed by twice weekly urine toxicology testing and self-report during the first 12 weeks and monthly during the 12-week extension, include resumption of heroin use, 1 and 3 weeks continuous relapse and reductions in hiv risk behaviors. the project will also evaluate the characteristics of treatment-seeking opioid addicts in iran (including specific risk behaviors and patterns of hiv risk behaviors; prevalence of psychiatric and other medical comorbidity; and patterns of social, family, vocational, and criminal activity and service needs-specific aim 2). this data will be used to revise the dc-hiv manual to address the specific circumstances and risk behaviors of opioid addicts in iran and to provide data regarding any differential response of opium compared to heroin addicts to bmt or nmt. finally, the project will also provide clinical training for health professionals and training and mentoring in drug abuse treatment and hiv prevention research to clinical researchers who will continue development, implementation, evaluation and dissemination of hiv prevention and drug abuse treatment approaches in iran after the project ends (specific aim 3). the institute for cognitive science studies will collaboratively fund the project and lead subsequent dissemination and drug abuse and hiv risk reduction efforts in iran.

Eligibility criteria:
inclusion criteria: * opioid dependence exclusion criteria: * dependence on alcohol, benzodiazepines or sedatives * suicide or homicide risk * psychotic disorder or major depression * inability to read or understand the protocol or assessment questions * life-threatening or unstable medical problems * greater than 3 times normal liver enzymes (ast, ggt)

Keywords: buprenorphine naltrexone hiv risk reduction behavior counseling hiv seronegativity
analgesia-based sedation during mechanical ventilation

Conditions: Ventilation, Mechanical; Respiratory Insufficiency; Critical Illness

Summary: hypothesis: a protocolized algorithm for sedation in critically ill patients on mechanical ventilation can decrease ventilator days, costs and improve outcome. this is a multicenter observational-interventional study on critically ill patients who require mechanical ventilation for more than 48 hours, involving 13 icu in chile. there are two periods (groups): a descriptive phase of sedation practices, and an interventional period in which an analgesia-based, goal-directed, nurse-driven sedation is applied. main outcome: ventilator-free days between both periods.

this is a multicenter observational-interventional study on critically ill patients who require mechanical ventilation for more than 48 hours, involving 13 icu in chile. main exclusion criteria are neurologic impairment, previous chronic cardiac, liver and renal failure, second period of mechanical ventilation during hospitalization, short term expected mortality. there is an initial descriptive phase of sedation practice, involving sedative drugs, sedation level assessment, and outcome: ventilator-free days, icu stay, costs and mortality. after a period of analysis and training, an analgesia-based, goal-directed, nurse-driven sedation protocol is applied. fentanyl infusion is started and titrated to obtain a patient calm and cooperative or mildly sedated while on mechanical ventilation. hypnotics and opiates i.v. boluses are allowed during the first hours of mechanical ventilation. midazolam infusion is started if ventilatory distress continue despite fentanyl 1.8 µg/kg/min. haldol, muscle relaxants and other sedative drugs are allowed depending on patient condition. after 48 hours of mechanical ventilation, sedative drugs are discontinued in the morning. main outcome: ventilator-free days. secondary outcome: icu stay, costs, and sedation quality. at 6 moths sf-36. each period is planned to included at least 140 patients, for a 20% difference in ventilator-free days, with 80% power and a 0.05 type i error.

Eligibility criteria:
inclusion criteria: * patients who require mechanical ventilation for more than 48 hours exclusion criteria: * nervous system diseases * previous liver or renal failure * second episode of mv during same hospitalization * expected mv shorter than 48 hours * short term expected mortality.

Keywords: ventilation, mechanical sedation
organoids in predicting chemoradiation sensitivity on rectal cancer

Conditions: Organoids; Rectal Cancer; Chemoradiation

Summary: patients with locally advanced rectal cancer will receive biopsy before the standard treatment of neoadjuvant chemoradiation. the investigators are going to establish organoids model from the pre-treatment biopsies and expose organoids to irradiation and the same chemotherapy drugs. the sensitivity of irradiation and chemotherapy drugs will be tested in the organoids model. here, the investigators will launch the observational clinical trial to validate whether the organoids could predict the clinical outcome in locally advanced rectal cancer patients underwent neoadjuvant chemoradiation.


Eligibility criteria:
inclusion criteria: * pathological confirmed adenocarcinoma * clinical stage t3-4 and/or n+ * the distance from anal verge less than 12 cm * without distance metastases * kps \>=70 * without previous anti-cancer therapy * sign the inform consent exclusion criteria: * pregnancy or breast-feeding women * serious medical illness * baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/l, hb≥90g/l, plt≥100×10\^9/l, alt/ast ≤2.5 uln, cr≤ 1 uln
outcomes data of adipose stem cells to treat osteoarthritis

Conditions: Osteoarthritis

Summary: the purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (svf), has on joint pain and functionality in people with osteoarthritis (oa). svf contains components with "regenerative" properties, including stem cells that have shown promise for ameliorating specific disease conditions. this study is designed to evaluate joint pain and functionality changes in individuals with oa for up to 12 months following svf treatment.


Eligibility criteria:
inclusion criteria: * fluent in english * over the age of 18 * diagnosed with oa of the knee and/or hip * scheduled for intravenous and intra-articular administrations of autologous svf * capable of understanding and willing to sign informed consent * willing and able to complete brief phone interviews * willing and able to complete online surveys exclusion criteria: * co-morbidity with an autoimmune disorder * pregnant, may become pregnant, or breastfeeding * subjects for which baseline data is not available
a study of hyaluronic acid injectable gel (vyc-25l) for restoration and creation of facial volume in the chin and jaw

Conditions: Chin Retrusion

Summary: this study will evaluate the safety and performance of vyc-25l hyaluronic acid injectable gel for the restoration and creation of facial volume in participants seeking to increase projection of the chin and/or jaw.


Eligibility criteria:
inclusion criteria: -has chin retrusion. exclusion criteria: * has ever received or is planning to receive permanent facial implants during the study. * has tattoos, piercings, facial hair or scars that would interfere with visual assessments of the chin or jaw. * has dentures or any device covering part of the palate or plans to undergo any dental procedure other than prophylaxis during the study. * has undergone semipermanent dermal filler treatment to the chin or jaw within 36 months or is planning treatment during the study. * has undergone any surgery of the chin or jaw area within 24 months or a planned surgery during the study. * has undergone mesotherapy, cosmetic resurfacing, or botulinum toxin injections within 6 months or a planned treatment during the study. * has experienced trauma to the chin and jaw area within 6 months. * has been previously diagnosed with streptococcal disease. * has a history of anaphylaxis or allergy to lidocaine, hyaluronic acid or streptococcal protein. * has porphyria or untreated epilepsy. * has active autoimmune disease. * has current cutaneous or mucosal inflammatory or infectious processes, abscess, an unhealed wound, or a cancerous or pre-cancerous lesion. * is on a concurrent regimen of lidocaine or structurally-related local anesthetics or is on a concurrent regimen of drugs that reduce or inhibit hepatic metabolism. * has impaired cardiac conduction, severely impaired hepatic function, or severe renal dysfunction. * is on an ongoing regimen of anti-coagulation therapy. * is on an ongoing regimen of medications (eg, aspirin, ibuprofen) or other substances known to increase coagulation time (eg, herbal supplements with garlic or gingko biloba) within the past 10 days. * has begun using any over-the-counter or prescription oral or topical, anti-wrinkle products below the subnasale within 30 days before enrollment or is planning to begin using such products during the study.
study of covid-19 prognostic factors in hospitalized patients

Conditions: COVID-19

Summary: severe covid-19 prognostic factors have been studied worldwide throughout the pandemic, but there is considerable variability. therefore, the investigators will summarize the identified prognostic factors in the international literature and will conduct a retrospective cohort study to identify the prognostic factors of severe covid-19 in hospitalized patients of the hospital de la santa creu i sant pau in barcelona (spain) between march 2020 and february 2021, compare them with those mentioned in the international literature and establish those most adequate to our population.

background: spain is one of the european countries most affected by the sars-cov-2 pandemic, with a fatality rate of 2.2%. faced with the significant number of patients requiring intensive care, the number of beds increased considerably in the span of 11 months to respond to the situation. there is still no drug treatment or specific prognostic factors for covid-19 that allow its proper management. objective: to study the prognostic factors of severity due to covid-19 in hospitalized patients at hospital de la santa creu i sant pau, and their comparison with the prognostic factors identified in the literature review. methods: in a first phase, the published studies will be reviewed to identify the existing prognostic factors through various platforms (medline, embase, cochrane). a retrospective cohort study will subsequently be carried out to determine the patients' characteristics and to identify the prognostic factors of severity. patients over 18 years of age, diagnosed with covid-19 and hospitalized between march 01, 2020 and february 28, 2021 will be included. a descriptive analysis of the cohort will firstly be performed, followed by an analysis of the possible prognostic factors through bivariate tests and multivariate analyzes. the occurrence of admission to intensive care, mortality, and hospital stay \> 30 days will be calculated with logistic regression (p \<0.05, a = 0.05, 95% confidence interval). finally, the prognostic factors identified in the literature review will be compared with those determined in the cohort.

Eligibility criteria:
inclusion criteria: * equal or older than 18 years old * hospitalized between march 1st, 2020, and february 28th, 2021. * be diagnosed with covid-19 disease exclusion criteria: * underaged patients * \> 16h stay in the emergency unit

Keywords: prognostic factors covid-19 hospitalization critical care all-cause mortality
efficacy and safety of egito association in the treatment of type ii diabetes mellitus and hypertension

Conditions: Hypertension Associated; Type II Diabetes Mellitus

Summary: the purpose of this study is to evaluate the efficacy and safety of egito association in the treatment of type 2 diabetes mellitus and hypertension


Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * participants of both sexes, with age greater than or equal to 18 years and less than or equal to 85 years; * participants presenting the diagnosis of type ii diabetes mellitus, and who did not reach the therapeutic goals of hba1c with previous dietary, physical exercise guidance and previous therapies at a stable dose in the last 3 months; * participants presenting the diagnosis of hypertension, and who did not reach the therapeutic goals with previous therapies. exclusion criteria: * any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants; * history of alcohol abuse or illicit drug use; * participation in a clinical trial in the year prior to this study; * pregnancy or risk of pregnancy and lactating patients; * known hypersensitivity to any of the formula compounds; * type 1 diabetes mellitus; * known or suspected secondary hypertension.

Keywords: hypertension type ii diabetes mellitus
pyramidal versus continuous training effects on fatty liver

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: exercise is very important maneuver in the control of elevated liver enzymes in complaint of fatty liver .. the exercise forma are many.. from these exercises, pyramidal training or continues aerobic one.

the total participating subjects of the two groups of this study will be fatty liver subjects (19 subjects in every group). aerobic training on electronic treadmill will be adopted for 60 minutes in one group. in the other group, a pyramidal training will be adopted for nearly 60 minutes (nearly two rounds of 21 minutes of running on electronic treadmill will be separated with 10 minutes of rest between the two rounds. also, warming (4 minutes before start of pyrimidal trianing) and cooling (4 minutes after pyramidal training) will be done through gentle stretching exercises/activities. the both forms of exercises will be done three times per week. the total study time will be 12 weeks. to be mentioned , the two groups followed low clorie diet

Eligibility criteria:
inclusion criteria: * fatty liver patients * obese patients * all patients will class one obesity exclusion criteria: * cardiovascular complaint * metabolic complaints * othopedic pains in lower limbs
l-til in patients with malignancy resistance to anti-pd-1 therapy

Conditions: Advanced Solid Tumor

Summary: safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-pd-1 therapy


Eligibility criteria:
inclusion criteria: * expected lifespan is over 3 months * malignant tumors diagnosed by pathological examination * imaging examination is at advanced stage with at least one measurable lesion * ineffective or resistant to previous anti-pd-1 therapy * ecog score 0-2 * adequate organ function * no other serious diseases that conflict with this protocol * women of childbearing age must check for a negative blood pregnancy test within 7 days, and subjects of childbearing age must use appropriate contraception during the test and within 3 months * witten informed consent from the patients exclusion criteria: * severe infectious disease within 4 weeks before enrollment * active hepatitis b or c virus or hiv infection * severe autoimmune disease or immunodeficiency disease * severe allergies * severe mental disorder * systematically used a large amount of glucocorticoids within 4 weeks before enrollment * with severe heart, liver, kidney insufficiency, diabetes and other diseases * participation in other clinical studies in the past 3 months or having been treated with other gene products

Keywords: liquid tumor-infiltrating lymphocytes anti-pd-1 resistance solid tumor
improvement of transient elastography applicability and diagnostic accuracy to identify significant fibrosis by experienced operators using the m and xl probe.

Conditions: Chronic Liver Diseases (CLD)

Summary: transient elastography (te)is the reference method to identify liver stiffness (lsm) but fails to obtain a measurement in 3% of cases and results are considered unreliable in 16%. the aim of this study is to evaluate the applicability and diagnostic accuracy of te performed by trained operators (\ 500 explorations) and after a third exploration using xl probe. inadequate lsm will be re-evaluated by experienced operators with the m (standard size) probe. a third register will be performed with xl (obese size) probe in those patients with inadequate m probe determination. diagnostic accuracy will be estimated in patients with liver biopsy to identify significant fibrosis with a te cut-off value of 7.6 kpa (kilo pascal).


Eligibility criteria:
inclusion criteria: * patients with chronic liver disease evaluated with te by trained operators (experience \<500 explorations). * signed inform consent. * aged between 18-90. exclusion criteria: * patients with ascites. * pregnancy.